Skip to main content
. Author manuscript; available in PMC: 2022 Nov 4.
Published in final edited form as: Cell Stem Cell. 2021 Sep 1;28(11):1966–1981.e6. doi: 10.1016/j.stem.2021.08.004

Figure 2. DDX41 haploinsufficiency confers HSPC competitive advantage.

Figure 2.

(A) Tamoxifen injection schedule of competitive BM transplants. (B) Representative flow cytometry plots of blood. (C) Percentage of CD45.2+ cells in the blood of competitive transplant recipients over 16 weeks (*P < 0.05; n = 7 mice per group). (D) Percent CD45.2+ in BM mononuclear cells (MNCs) and LSK of competitive transplant recipient mice 16 weeks post-tamoxifen. (*P < 0.01; n = 7 mice per group) (E) Percent CD45.2+ in BM LT-HSC (LSK CD48−CD150+), HPC-1 (LSK CD48+CD150−), HPC-2 (LSK CD48+CD150+), and MPPs (LSK CD48−CD150−) of competitive transplant recipient mice 16 weeks post-tamoxifen (*P < 0.05). (F) Percentage of CD45.2+ cells in the blood of secondary transplant recipients over 16 weeks (*P < 0.01; n = 3 mice per group). (G) Percent CD45.2+ in BM MNCs of secondary competitive transplant recipient mice 16 weeks post-tamoxifen (*P < 0.01). (H) Percent CD45.2+ in the LSK gate of secondary competitive transplant recipient mice 16 weeks post-tamoxifen (*P < 0.05).